{"id":"metronidazole-0-75-cream","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or burning at application site"},{"rate":null,"effect":"Dryness or peeling"},{"rate":null,"effect":"Metallic taste (systemic absorption)"},{"rate":null,"effect":"Contact dermatitis"}]},"_chembl":{"chemblId":"CHEMBL137","moleculeType":"Small molecule","molecularWeight":"171.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metronidazole is a nitroimidazole antimicrobial that generates reactive oxygen species and damages microbial DNA, resulting in bactericidal and antiprotozoal effects. In rosacea, it reduces the population of Demodex mites and associated bacteria, thereby decreasing inflammation and erythema. The topical 0.75% cream formulation delivers the drug directly to affected skin areas.","oneSentence":"Metronidazole disrupts bacterial and protozoal DNA, leading to cell death and reduction of microorganisms associated with rosacea and other inflammatory skin conditions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:03.372Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rosacea (topical treatment)"},{"name":"Bacterial vaginosis (systemic formulations; topical cream may be used off-label)"}]},"trialDetails":[{"nctId":"NCT05929794","phase":"PHASE4","title":"Pharmacokinetics of Transdermal Metronidazole","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Iowa","startDate":"2024-02-26","conditions":"Healthy","enrollment":24},{"nctId":"NCT02602470","phase":"","title":"Preferences & Treatment Satisfaction Drivers in Rosacea Patients","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01-08","conditions":"Rosacea","enrollment":206},{"nctId":"NCT03412071","phase":"NA","title":"Effect of Antibiotics on Penile Microbiome and HIV Susceptibility Study in Ugandan Men","status":"UNKNOWN","sponsor":"University of Toronto","startDate":"2017-12-07","conditions":"Foreskin HIV Susceptibility","enrollment":125},{"nctId":"NCT01493947","phase":"PHASE3","title":"CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-04","conditions":"Papulopustular Rosacea","enrollment":962},{"nctId":"NCT02052999","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients","status":"COMPLETED","sponsor":"Amorepacific Corporation","startDate":"2013-02","conditions":"Erythematotelangiectatic Rosacea, Papulopustular Rosacea","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Metronidazole"],"phase":"phase_3","status":"active","brandName":"Metronidazole 0.75% cream","genericName":"Metronidazole 0.75% cream","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metronidazole disrupts bacterial and protozoal DNA, leading to cell death and reduction of microorganisms associated with rosacea and other inflammatory skin conditions. Used for Rosacea (topical treatment), Bacterial vaginosis (systemic formulations; topical cream may be used off-label).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}